EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment

Ananya H Elati, Erika W Davies, Mark V Mishra, Jeffrey A Winkles, Graeme F Woodworth, Anthony J Kim

Advanced Drug Delivery Reviews · 2026-05 · 232 · 115811

DOI: 10.1016/j.addr.2026.115811 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-05. Verfasst von Ananya H Elati und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21202, United States; University of Maryland Marlene and Stewart…. Hauptthemen laut MEDLINE: Glioblastoma, Radiation-Sensitizing Agents, Brain Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, BLRD VA, United States Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is a highly lethal brain cancer with poor patient prognosis and limited treatment options. Standard-of-care therapy involves maximally safe surgical resection followed by radiation therapy (RT) in combination with the alkylating agent temozolomide (TMZ) to treat the residual and brain-invading components of the disease. While RT remains a central part of definitive treatment, its efficacy is limited by intrinsic and acquired radiation resistance, making long-term tumor control and survival rare. While TMZ provides modest anti-tumor benefits, tumor resistance to TMZ and lack of synergy with RT underscore the critical need to identify novel therapeutic strategies that can enhance RT efficacy. Platinum-based chemotherapeutics have emerged as promising radiosensitizers due to their ability to augment RT-induced DNA double-strand breaks, while also triggering oxidative stress, endoplasmic reticulum stress, immunogenic cell death, and apoptosis. Such multimodal mechanisms of action may propel platinum-based drugs to the forefront of GBM treatment and overcome the adaptive survival pathways that underlie radiation resistance. This is particularly the case as advances in drug delivery strategies, such as liposome- and nanocomplex-based formulations, are being developed to improve brain penetration, tumor accumulation, and reduce systemic toxicity-critical challenges that have historically limited the clinical application of platinum-based drugs in GBM. This review provides clinical relevance, mechanisms, delivery strategies, challenges, and recent advancements in the use of platinum compounds as radiosensitizers for GBM treatment, highlighting key preclinical studies, clinical observations, and future directions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaRadiation-Sensitizing AgentsBrain NeoplasmsAntineoplastic AgentsHumansAnimalsDrug Delivery Systems

Stichwörter der Autor:innen

Drug deliveryFocused ultrasoundGlioblastoma (GBM)Multimodal therapyNanoformulationsPlatinumRadiosensitization

Substanzen

Radiation-Sensitizing AgentsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD 21202, United States; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, United S…
  • Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
  • University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, United States; Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, Un…

Förderung

  • NCI NIH HHS
  • BLRD VA
  • United States Department of Veterans Affairs
  • NINDS NIH HHS
  • US Department of Veterans Affairs
  • NIH

Zitieren

APA

Elati, A. H., Davies, E. W., Mishra, M. V., Winkles, J. A., Woodworth, G. F., & Kim, A. J. (2026). Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment. Advanced Drug Delivery Reviews, 232, 115811. https://doi.org/10.1016/j.addr.2026.115811

Vancouver

Elati AH, Davies EW, Mishra MV, Winkles JA, Woodworth GF, Kim AJ. Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment. Advanced Drug Delivery Reviews. 2026;232:115811. doi:10.1016/j.addr.2026.115811

BibTeX
@article{Elati2026,
  author = {Elati, Ananya H and Davies, Erika W and Mishra, Mark V and Winkles, Jeffrey A and Woodworth, Graeme F and Kim, Anthony J},
  title = {Platinum-based therapeutics as emerging multi-modal radiosensitizers in glioblastoma treatment},
  journal = {Advanced Drug Delivery Reviews},
  year = {2026},
  volume = {232},
  pages = {115811},
  doi = {10.1016/j.addr.2026.115811}
}
Kostenlos starten →